StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) income statement

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$68.29−0.21 (-0.31%)

Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –

Exelixis, Inc. income statement

Ratios

Latest available, balances at Oct 2, 2026

Profitability, TTM

Gross margin
96.3%
Operating margin
40.2%
Net margin
35.5%
Return on equity, FY2025
35.5%

Financial strength

Current ratio
3.21
Debt to equity
–
Debt to assets
–
Cash to current liabilities
74.0%

Valuation

P/E ratio
20.4
Price to sales
6.67
Price to book
9.09
Dividend yield
–

See a number that looks wrong?